Concepedia

Author

Tomonori Hirashima

Osaka Prefectural Medical Center

Also Known As

Hirashima Tomonori, TOMONORI HIRASHIMA, Tomonori HIRASHIMA, Tomonori Hirashima

214

Publications

12.9K

Citations

40

H-Index

68

Concepts

All Affiliations

Osaka Prefectural Medical CenterNHO Kinki Chuo Chest Medical CenterOsaka International Cancer InstituteKindai UniversityOsaka City General Hospital
TH

About

Tomonori Hirashima is an author at Osaka Prefectural Medical Center specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

41

6.5K

2

Health Sciences

6

6

227

3

Public Health

2

2

191

4

Engineering

1

1

10

5

Allergy

1

1

24

Tomonori Hirashima

×

100

Publications

12.4K

Citations

39

H-Index

YearCitations

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe,

The Lancet Oncology

2009

4.1K

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba,

The Lancet

2019

3.2K

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto,

The Lancet Oncology

2019

594

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim,

The Lancet Oncology

2018

568

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim,

Journal of Clinical Oncology

2017

563

Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study

Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita,

Journal of Clinical Oncology

2010

163

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe,

Journal of Clinical Oncology

2012

145

Pretreatment advanced lung cancer inflammation index (<scp>ALI</scp>) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Takayuki Shiroyama, Hidekazu Suzuki, Motohiro Tamiya,

Cancer Medicine

2017

121

Proteomics‐based identification of α‐enolase as a tumor antigen in non‐small lung cancer

Ping He, Tetsuji Naka, Satoshi Serada,

Cancer Science

2007

108

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial

Motohiro Tamiya, Akihiro Tamiya, Takako Inoue,

PLoS ONE

2018

105

Page 1